Content Navigation
( All
None )
Target General Information |
Top |
Target ID |
T71205 |
Target Info
|
Target Name |
Myeloid inhibitory C-type lectin-like receptor (CD371) |
Synonyms |
MICL; Dendritic cell-associated lectin 2; DCAL2; DCAL-2; CLL1; CLL-1; C-type lectin-like molecule 1; C-type lectin domain family 12 member A |
Target Type |
Clinical trial Target |
Gene Name |
CLEC12A |
UniProt ID |
|
Targeted Antigens of CAR-T Cell Therapy |
Top |
CAR T-Cell Therapy Drug(s) |
CAR-T cells targeting CLL1 |
Drug Info
|
Phase 1/2 |
Multiple myeloma |
[1] |
CLL1-specific gene-engineered T cells |
Drug Info
|
Phase 1/2 |
Acute myeloid leukaemia |
[2] |
CLL1-CD33 cCART cell therapy |
Drug Info
|
Phase 1 |
Acute myeloid leukaemia |
[3] |
UCART-CLL1 |
Drug Info
|
Preclinical |
Multiple myeloma |
[4] |
References |
Top |
REF 1 |
ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
|
REF 2 |
ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
|
REF 3 |
Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
|
REF 4 |
Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020 Mar;19(3):185-199.
|
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.